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Improvement in early detection and treatment of breast cancer has 
resulted in increased long-term breast cancer survivors.1 The cor-
nerstone of breast cancer management still is surgery. In breast can-
cer surgery, equal survival rates are achieved, irrespective of type of 
surgery performed.2-4 However, breast cancer surgery can adversely 
affect women's psychological health and health-related quality of life 
(HRQoL). Prediction of long-term physical, sexual, and psychosocial 
outcomes is therefore very important in treatment decision-making.
Patient-reported outcomes (PROs) come directly from the pa-
tient without interpretation by a health care provider and reflect 
aspects of health, quality of life, and related constructs.5 The rou-
tine collection of PROs has been implemented in many health insti-
tutions,6-10 and it is clear that PROs have an important role in today's 
clinical practice. Collaboration of the International Consortium for 
Health Outcomes Measurement (ICHOM) with several other health 
care institutions worldwide has resulted in the development of a 
Standard Set for breast cancer outcomes.10 Within this outcome 
set, patient-reported outcome measures (PROMs) are pivotal and 
accounting for 75% of the outcomes evaluated.10
PROs can help facilitate in shared decision-making through in-
forming treatment decisions and setting expectations. The ability 
for patients to understand what other patients with breast cancer 
experienced after surgery is thereby vital.
Predictive modeling is not new to medicine. In clinical medicine, a 
multivariable prediction model combines information from multiple 
predictors to predict the probability of or risk for a specific disease 
or outcome.11 Predictive modeling has the purpose of informing pa-
tients and guiding clinicians in decision-making on treatment deci-
sions. The majority contains prediction of patient outcomes focused 
on cancer survival and risk of cancer recurrence/local control,12-14 
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Abstract
As high breast cancer survival rates are achieved nowadays, irrespective of type of 
surgery performed, prediction of long-term physical, sexual, and psychosocial out-
comes is very important in treatment decision-making. Patient-reported outcomes 
(PROs) can help facilitate this shared decision-making. Given the significance of more 
personalized medicine and the growing trend on the application of machine learn-
ing techniques, we are striving to develop an algorithm using machine learning tech-
niques to predict PROs in breast cancer patients treated with breast surgery. This 
short communication describes the bottlenecks in our attempt to predict PROs.
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but little has been done to predict PROs into the future. Moreover, 
to our knowledge, there are no tools available focusing on predict-
ing HRQoL outcomes after breast surgery into the future. Given the 
significance of more personalized medicine and the growing trend 
on the application of machine learning techniques, our breast can-
cer team is striving to develop an algorithm using machine learning 
techniques to predict PROs in breast cancer patients treated with 
breast surgery.
We aimed to develop and validate a simple prediction model 
for improvement of HRQoL after breast cancer surgery using 
data from three PRO questionnaires as proposed in the ICHOM 
Standard Set for Breast Cancer, namely the EORTC QLQ-C30 
and EORTC QLQ-B23, and the BREAST-Q (postoperative mod-
ules). To this end, a retrospective cohort collected and described 
previously6 was used. This cohort contained 764 female patients 
with breast cancer (pTis-3N0-3M0) who underwent breast cancer 
surgery between January 2005 and September 2016 at Erasmus 
MC Academic Breast Cancer Center, Rotterdam, the Netherlands. 
Data on patient characteristics, age, date and type of surgery, 
tumor morphology, TNM staging (7th edition15), hormonal status, 
HER2 status, BRCA 1/2 gene mutation status, local recurrence, 
second primary breast cancer, details regarding chemotherapy 
and/or immunotherapy and endocrine therapy, radiotherapy, 
and follow-up were available. Machine learning (ie, general lin-
ear model regression (GLM), support vector machines (SVM), 
single-layer artificial neural networks (ANN), and deep earning 
(DL))16 was used to jointly study presurgical prognostic variables 
relating to age, medical status, tumor characteristics, and possi-
ble (neo)adjuvant treatment indications/treatment characteristics. 
Unfortunately, a lack of relationship was found between outcome 
variables and their predictors, meaning that the accuracy reflected 
just the population prevalence of the outcomes. Machine learn-
ing models have an immense number of parameters that must be 
either learned using data or set manually by the researcher.17 By 
combining variables in a reduced number of dimensions, we tried 
to help the analysis, but this did not yield substantial changes and 
required days of computational time.
During the process, some crucial obstacles were identified, 
which stagnated the development of a machine learning model in 
this dataset. This included the cross-sectional design, the lack of 
baseline PROs, and the relative small sample size. Given the in-
crease in the use of machine learning techniques in medical re-
search and the, worldwide, desire to predict and influence PROs 
after breast surgery, we believe it is important to draw attention 
to our findings.
Machine learning describes the use of computer algorithms 
that learn nonlinear associations retrospectively from the data to 
estimate risk of a specific outcome. Even though machine learning 
is increasingly used in medical research,18-20 success is not always 
guaranteed. As with any method, a good understanding of the prob-
lem and an appreciation of the limitations of the dataset is important. 
Also crucial is an understanding of the assumptions and limitations 
of the algorithms being applied. If a machine learning experiment 
is properly designed, with correctly implementation and validated 
results, there usually is a good chance of success.
Although we used patient and treatment characteristics, 
and outcomes of interest to both patients and clinician (ie, vali-
dated PROMs as proposed in the ICHOM Standard Set for Breast 
Cancer), there were some important limitations in using the ex-
isting dataset.6 With 764 breast cancer patients, the study was 
relatively large, although for machine learning techniques prob-
ably not large enough. The size of the dataset is one of the most 
common limitations noted in studies reporting machine learning 
techniques.14 The dataset needs to be sufficiently large, which al-
lows sufficient partitioning into training and testing sets, leading 
to reasonable validation of the estimators14 in order to enhance 
the generalizability of the predictive model.
The most important limitation however is the cross-sectional 
design of the dataset, meaning the absence of baseline PROs. 
Traditional methods for evaluating PROMs look at the change over 
time, using the baseline compared with the end point. Enabling com-
parison with preoperative PROs is expected to reflect the influence 
of different treatments on HRQoL outcomes better than a single 
score obtained following treatment. One explanation probably is the 
fact that not every individual patient will score their breasts to the 
highest possible level at baseline. Although preoperative PROs were 
not available, all known other potential predictors were assessed, 
except for socioeconomic status (which cannot be easily obtained in 
the Netherlands for privacy reasons). The next step toward further 
validation of this approach to prediction would be to work with a 
more complete dataset, including baseline PROs and lifestyle mea-
sures. The research team has secured a prospective dataset over 
a longer time frame, but this dataset currently consists of a small 
number of patients. Since PROM collection is considered standard 
of care at our institute nowadays,9 in combination with a regional 
and international collaboration, this cohort will be progressively en-
larged over time. There are plans in place to develop and test the 
performance of the machine learning techniques in this dataset in 
the near future. However, the above-described study was a valuable 
first step toward modeling PROM data for use in breast cancer sur-
gery. Once developed, the model could have potential for use out-
side breast surgery because similar sets are used in other diseases. 
But, as also suggested by Beam et al,17 the challenges and obstacles 
to reproducibility of machine learning techniques must be carefully 
considered to ensure the validation, safety, and effectivity of these 
new class of prediction tools.
In conclusion, using machine learning methods, we endeavored 
to develop a clinical prediction model for PROs after breast surgery. 
Clinicians could use information on the level of patient HRQoL out-
come improvement, when counseling patients about the (prognos-
tic) outcomes of breast cancer surgery, allowing patients to be more 
involved in their treatment decision. To actually realize an effective 
clinical prediction model, information regarding patients’ starting 
position is crucial. This emphasizes the urgent need of collecting 
PROMs at baseline, leading to the opportunity of predictive model-
ing on PROMs in breast cancer surgery in the future.
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